Sol Gel Technologies Ltd Quick Ratio (SLGL) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Sol gel Technologies Ltd   (NASDAQ: SLGL)

Sol Gel Technologies Ltd 's Quick Ratio

SLGL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 2.63 below Sol Gel Technologies Ltd average.

Within Major Pharmaceutical Preparations industry 154 other companies have achieved higher Quick Ratio than Sol Gel Technologies Ltd in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 539, from total ranking in the third quarter 2025 at 627.

Explain Quick Ratio?
How much Cash & cash equivalents SLGL´s has?
What are SLGL´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SLGL Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 43.11 % 16.76 % -12.54 % 16.76 % -3.5 %
Y / Y Cash & cash equivalent Change -0.07 % 0.31 % -20.3 % 0.31 % -37.03 %
Quick Ratio MRQ 2.63 3.89 4.26 3.89 3.77
SLGL's Total Ranking # 539 # 627 # # #
Seq. Current Liabilities Change 47.17 % 8.21 % -7.58 % -2.76 % 20.08 %
Seq. Cash & cash equivalent Change -0.38 % -1.19 % 1.2 % 0.31 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 155
Healthcare Sector # 260
Overall Market # 539


Quick Ratio Statistics
High Average Low
10.1 5.42 0.16
(Dec 31 2022)   (Dec 31 2021)




Financial Statements
Sol Gel Technologies Ltd 's Current Liabilities $ 9 Millions Visit SLGL's Balance sheet
Sol Gel Technologies Ltd 's Cash & cash equivalent $ 24 Millions Visit SLGL's Balance sheet
Source of SLGL's Sales Visit SLGL's Sales by Geography


Cumulative Sol Gel Technologies Ltd 's Quick Ratio

SLGL's Quick Ratio for the trailling 12 Months

SLGL Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 15.74 % 3.06 % 2.62 % 9.47 % 9.24 %
Y / Y Cash & cash equivalent TTM Growth -5.92 % -17.29 % -26.27 % -25.03 % -32.08 %
Quick Ratio TTM 3.55 3.94 4.09 4.21 4.36
Total Ranking TTM # 3545 # 3437 # # #
Seq. Current Liabilities TTM Growth 11.22 % 3.77 % -3.36 % 3.78 % -0.97 %
Seq. Cash & cash equivalent TTM Growth -0.02 % 0.08 % -6.05 % 0.07 % -12.1 %

Quick ratio ranking by company, industry and sector >> Back to SLGL Financial Strength Comparisons >> Go to Compare SLGL Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q4 2025 to $9.08 millions, cumulative Quick Ratio decreased to 3.55 below the Sol Gel Technologies Ltd average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 428 other companies have achieved higher Quick Ratio than Sol Gel Technologies Ltd . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 3437 to 3545.

Explain Quick Ratio?
How much Cash & cash equivalents SLGL´s has?
What are SLGL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 429
Healthcare Sector # 870
Within the Market # 3545


trailing twelve months Quick Ratio Statistics
High Average Low
10.1 5.54 0.15
(Dec 31 2022)   (Dec 31 2021)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Marker Therapeutics inc   7.07 $ 16.068  Millions$ 2.274  Millions
Camp4 Therapeutics Corporation  7.06 $ 109.517  Millions$ 15.514  Millions
Barinthus Biotherapeutics Plc  7.03 $ 70.456  Millions$ 10.018  Millions
Xenon Pharmaceuticals Inc   7.02 $ 548.886  Millions$ 78.167  Millions
Stablecoin Development Corporation  6.97 $ 7.958  Millions$ 1.142  Millions
Centessa Pharmaceuticals Plc  6.86 $ 294.580  Millions$ 42.935  Millions
Tonix Pharmaceuticals Holding Corp   6.73 $ 207.637  Millions$ 30.837  Millions
Zentalis Pharmaceuticals Inc   6.73 $ 245.893  Millions$ 36.559  Millions
An2 Therapeutics Inc   6.65 $ 58.001  Millions$ 8.720  Millions
Actinium Pharmaceuticals Inc  6.62 $ 47.998  Millions$ 7.247  Millions
Gain Therapeutics inc  6.45 $ 20.838  Millions$ 3.233  Millions
Nuvation Bio Inc   6.44 $ 529.211  Millions$ 82.231  Millions
Vistagen Therapeutics Inc   6.38 $ 80.482  Millions$ 12.612  Millions
Arcturus Therapeutics Holdings Inc   6.35 $ 230.909  Millions$ 36.379  Millions
Wave Life Sciences Ltd   6.33 $ 602.068  Millions$ 95.065  Millions
Korro Bio Inc   6.30 $ 75.156  Millions$ 11.937  Millions
Rocket Pharmaceuticals Inc   6.25 $ 188.929  Millions$ 30.206  Millions
Alzamend Neuro Inc   6.22 $ 3.949  Millions$ 0.635  Millions
Hepion Pharmaceuticals Inc   6.11 $ 1.828  Millions$ 0.299  Millions
Anebulo Pharmaceuticals Inc   6.09 $ 9.042  Millions$ 1.486  Millions
Ars Pharmaceuticals Inc   6.06 $ 244.986  Millions$ 40.421  Millions
Corvus Pharmaceuticals Inc   6.05 $ 56.750  Millions$ 9.380  Millions
Inmed Pharmaceuticals Inc  5.92 $ 10.787  Millions$ 1.822  Millions
Lipocine Inc   5.91 $ 14.930  Millions$ 2.528  Millions
Galmed Pharmaceuticals Ltd   5.90 $ 18.459  Millions$ 3.128  Millions
Generate Biomedicines Inc   5.71 $ 221.837  Millions$ 38.829  Millions
Kura Oncology Inc   5.70 $ 667.240  Millions$ 116.974  Millions
Annexon Inc   5.59 $ 238.345  Millions$ 42.630  Millions
Puretech Health Plc  5.59 $ 258.842  Millions$ 46.309  Millions
Oramed Pharmaceuticals Inc  5.55 $ 62.343  Millions$ 11.223  Millions

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.